LONDON–(BUSINESS WIRE)–Clarify Pharma, an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce its intention to apply for admission of its Ordinary Shares to trading on the Access segment of Aquis Stock Exchange Growth Market (AQSE) in London, UK.
The flotation is expected to value Clarify Pharma at approximately £10.5m. The Company plans to raise approximately £5m before expenses, by way of a placing of 167 million ordinary shares at 3p each through First Sentinel Corporate Finance, the Company’s corporate adviser and joint broker alongside Tennyson Securities. First dealings in the shares are expected to commence later this month.
Psychedelics are a class of substances whose primary effect is to trigger non-ordinary stages of consciousness via serotonin receptor agonism. This effect can cause specific psychological, visual and auditory changes and often a substantially altered state of consciousness. The potential benefits of psychedelic drugs have…
